HCV, HIV opt-out testing program to now be evaluated nationwide
A team of researchers, backed by a grant totaling more than $3 million, will study the feasibility of a nationwide opt-out testing program to detect…
Steve Bryson, PhD, Science Writer — 
Articles by Steve Bryson
FDA breakthrough designation granted to larsucosterol for AH
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to larsucosterol, Durect’s investigational therapy for people with severe alcohol-associated hepatitis…
Seladelpar eases liver damage, itch in primary biliary cholangitis
One year of treatment with Gilead Sciences’ seladelpar normalized biomarkers of liver injury and rapidly reduced itch for most people with primary biliary…
Low-dose soybean emulsion may avoid newborn cholestasis: Study
A reduced dose of soybean fat emulsion seems to be better than the standard dose at preventing parenteral nutrition-associated cholestasis in newborns undergoing surgery…
Triple blood test may be best at diagnosing biliary atresia
The blood levels of two proteins, called MMP-7 and SOX9, are significantly higher in infants with biliary atresia than in those with similar liver…
World Liver Day to raise awareness of Alagille, other liver diseases
April 19 is a day set aside to raise awareness of liver diseases such as Alagille syndrome. It’s World Liver Day, a global…
Canada unlikely to hit 2030 hepatitis C elimination target: Study
Current screening and treatment strategies won’t allow Canada to eliminate new cases of hepatitis C by 2030, a population modeling study found. That’s the…
Ascletis to stop clinical testing of ASC42 in primary biliary cholangitis
Ascletis Pharma will not to pursue further clinical testing of its experimental oral therapy ASC42 for adults with primary biliary cholangitis (PBC). The…
Blood protein predicts post-transplant liver fibrosis in biliary atresia
A blood test that measures the levels of the M2BPGi protein accurately predicts the presence of moderate liver scarring, or fibrosis, in children and adolescents…
Phase 1b/2 trial of golexanolone for PBC behavioral symptoms advances
Golexanolone, Umecrine Cognition’s investigational oral therapy, was generally safe and well tolerated in adults with primary biliary cholangitis (PBC) and clinically significant…